Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-26T00:43:39.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Schizophrenia in the elderly: a special case requiring special management?

Published online by Cambridge University Press:  16 April 2020

Carlo Altamura  and
Tony Elliott
Carlo Altamura*
Affiliation:
Chair of Psychiatry, University of Milan, Via G.B. Grassi 74, 20127Milan, Italy
Tony Elliott
Affiliation:
Services for Older People, Shelton Hospital, ShrewsburySY3 8DN, UK
*
*Corresponding author. E-mail address: E-mail address:[email protected] (C.Altamura).
Get access

Extract

As the life expectancy of the general population increases, the population of elderly people with schizophrenia is also expected to increase. Consideration of the particular needs of these patients and the challenges associated with their management is therefore important [45].

Type
Research Article
Information
European Psychiatry , Volume 18 , Issue S2: Schizophrenia: Improving the treatment through increased understanding - Mind Matters 4th International Psychiatry Forum , December 2003 , pp. 46s - 53s
Copyright
Copyright © 2003 European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adamis, D, Ball, C.Physical morbidity in elderly psychiatric inpatients: prevalence and possible relations between the major mental disorders and physical illness. Int J Genatr Psychiatry 2000; 15(3): 248–53.Google ScholarPubMed
Almeida, OP, Howard, RJ, Levy, R, David, ASPsychotic states arising in late life (late paraphrenia). The role of risk factors. Br J Psychiatry 1995:166(2):215–28.CrossRefGoogle ScholarPubMed
Altamura, AC, Curreli, R.Antipsychotics in the elderly: the use of ‘typical’ vs ‘atypical’ compounds. In: Mental disorders in the elderly: new therapeutic approaches. Int Acad Biomed Drug Res 1998;13:125–37.CrossRefGoogle Scholar
Altamura, AC, Cavallaro, R, Regazzetti, MG. Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics. Eur Arch Gen Psychiatry Clin Neurosci 1990;240:9–12.CrossRefGoogle Scholar
Altamura, AC, Mauri, MC, Girardi, T, Panetta, B.Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. Int J Clin Pharmacol Res 1990:(4):223–8.Google ScholarPubMed
Barak, Y, Aizenberg, D, Mirecki, Iet al. Very late-onset schizophrenia-like psychosis: clinical and imaging characteristics in comparison with elderly patients with schizophrenia. J Nerv Ment Dis 2002;190(11):733–6.CrossRefGoogle ScholarPubMed
Bilder, RM, Goldman, RS, Volavka, Jet al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018–28CrossRefGoogle ScholarPubMed
Branin, JJ.The role of memory strategies in medication adherence among the elderly. Home Health Care Serv Q 2001;20(2):1–16.CrossRefGoogle ScholarPubMed
Byerly, MJ, Weber, MT, Brooks, DLet al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001;18(1):45–61CrossRefGoogle ScholarPubMed
Castle, DJ, Murray, RMThe epidemiology of late-onset schizophrenia. Schizophr Bull 1993;19(4):691–700CrossRefGoogle ScholarPubMed
Cohen, CI, Schoos, R.Schizophrenia. Management issues that complicate care of older persons. Geriatrics 2002;57(9):39–40.Google ScholarPubMed
Copeland, JR, Dewey, ME, Scott, Aet al. Schizophrenia and delusional disorder in older age: community prevalence, incidence, comorbidity, and outcome. Schizophr Bull 1998;24(1):153–61.CrossRefGoogle ScholarPubMed
Crome, P, Flanagan, RJ. Pharmacokinetic studies in elderly people. Are they necessary? Clin Pharmacokinet 1994;26(4)-243–7.CrossRefGoogle ScholarPubMed
Dolder, CR, Jeste, DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53(12):1142–5.CrossRefGoogle ScholarPubMed
Forsell, Y, Palmer, K, Fratiglioni, L.Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand 2003,179;25-8.CrossRefGoogle ScholarPubMed
Goldberg, RJ.Tardive dyskinesia in elderly patients: an update. J Am Med Dir Assoc 2003;4(2)S32-S42.CrossRefGoogle ScholarPubMed
Goldman, LS.Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60(21): 10–15.Google ScholarPubMed
Gournellis, R, Lykouras, L, Fortos, Aet al. Psychotic (delusional) major depression in late life: a clinical study. Int J Geriatr Psychiatry 2001;16(11): 1085–91.CrossRefGoogle ScholarPubMed
Graham, JE, Rockwood, K, Beattie, BLet al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349(9068);1793–6.CrossRefGoogle Scholar
Gray, SL, Mahoney, JE, Blough, DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother 2001;35(5):539-45.CrossRefGoogle ScholarPubMed
Gregory, C, McKenna, P.Pharmacological management of schizophrenia in older patients. Drugs Aging 1994;5(4):254–62.CrossRefGoogle ScholarPubMed
Grossberg, GT, Grossberg, JA. Epidemiology of psychotherapeutic drug use in older adults. Clin Geriatr Med 1998;14(1):l–5.CrossRefGoogle ScholarPubMed
Harvey, PD, Green, MF, McGurk, SRet al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 2003; 169: 404–11.CrossRefGoogle ScholarPubMed
Henderson, AS, Korten, AE, Levings, Cet al. Psychotic symptoms in the elderly: a prospective study in a population sample. Int J Geriatr Psychiatry 1998;13(7):484–92.3.0.CO;2-7>CrossRefGoogle Scholar
Howard, R, Rabins, PV, Seeman, MVet al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatry 2000;157(2):172–8.CrossRefGoogle Scholar
Jensen, J, Nyberg, L, Gustafson, Y.et al. Fall and injury prevention in residential care - effects in residents with higher and lower levels of cognition J Am Genatr Soc 2003;51(5):627–35.CrossRefGoogle ScholarPubMed
Jeste, DV, Caligiuri, MP, Paulsen, JSet al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52(9) 756–65CrossRefGoogle ScholarPubMed
Jeste, DV, Akiko Gladsjo, J, Lindamer, LAet al. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22(3):413–30.CrossRefGoogle Scholar
Kane, JM, Woerner, M, Lieberman, J.Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;2:72–8.Google Scholar
Keefe, RS, Silva, SG, Perkins, DO, Lieberman, JA. The effects of novel antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201–22.CrossRefGoogle Scholar
Kendrick, R, Bayne, J.Compliance with prescribed medications by older adult patients. J Can Med Assoc 1982:127:961.Google Scholar
Lambert, TJ, Castle, DJ. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003;178:S57-S61.CrossRefGoogle ScholarPubMed
Legangneux, E, McEwen, J, Wesnes, KAet al. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol 2000;14(2):164–71.CrossRefGoogle Scholar
Lyketsos, CG, Lopez, O, Jones, Bet al. Prevalence of neuropsychiatrie symptoms in dementia and mild cognitive impairment. J Am Med Assoc 2002;288(12):1475–83.CrossRefGoogle Scholar
McShane, R, Keene, J, Gedling, Ket al. Do neuroleptic drugs hasten cognitive decline in dementia9 Prospective study with necropsy follow-up. Br Med J 1997;314(7076):266–70.CrossRefGoogle ScholarPubMed
Morris, JC, Rubin, EH, Moms, EJet al. Senile dementia of the Alzheimer's type: an important risk factor for serious falls. J Gerontol 1987,42(4):412–7.CrossRefGoogle ScholarPubMed
Ȯstling, S, Skoog, I.Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry 2002:59(1):53-9.CrossRefGoogle Scholar
Palmer, BW, Heaton, RK, Gladsjo, JA, Evans, JD, Patterson, TL, Golshan, Set al. Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophr Res 2002;55(3):205–15.CrossRefGoogle ScholarPubMed
Pollock, BG, Mulsant, BH. Antipsychotics in older patients. A safety perspective. Drugs Aging 1995;6(4):312–23.CrossRefGoogle ScholarPubMed
Richelson, E.Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(10):5–14.Google ScholarPubMed
Ritchie, CW, Chiù, E, Harrigan, S, Hall, K, Hassett, A, Macfarlane, Set al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18(5):432–40.CrossRefGoogle ScholarPubMed
Sable, JA, Jeste, DV. Antipsychotic treatment for late-life schizophrenia. Curr Psychiatry Rep 2002;4(4):299–306.CrossRefGoogle ScholarPubMed
Scharf, S, Christophidis, N.Prescribing for the elderly: relevance of pharmacokinetics and pharmacodynamics. Med J Aust 1993; 158(6):395–402.CrossRefGoogle ScholarPubMed
Tandon, R.Safety and tolerability: how do newer generation 'atypical' antipsychotics compare? Psychiatr Q 2002;73(4):297–311.CrossRefGoogle ScholarPubMed
Tariot, PN.The older patient: the ongoing challenge of efficacy and tolerability. J Clin Psychiatry 1999;60(23):29–33.Google ScholarPubMed
Tariot, PN, Salzman, C, Yeung, PP, Pultz, J, Rak, IW. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22(9): 1068–84.CrossRefGoogle ScholarPubMed
Tinetti, ME, Williams, CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997;337(18):1279–84CrossRefGoogle ScholarPubMed
Tinetti, ME, Speechley, M, Ginter, SF. Risk factors for falls among elderly persons living in the community N Engl J Med 1988, 319(26): 1701–7.CrossRefGoogle ScholarPubMed
van Os, J., Howard, R, Takei, Net al. Increasing age is a risk factor for psychosis in the elderly. Soc Psychiatry Psychiatr Epidemiol 1995; 30(4):161–4CrossRefGoogle ScholarPubMed
Webster, J, Grossberg, GT. Late-life onset of psychotic symptoms. Am J Geriatr Psychiatry 1998;6(3): 196–202.CrossRefGoogle ScholarPubMed
Weickert, TW, Goldberg, TE, Marenco, S, Bigelow, LB, Egan, MF, Weinberger, DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003;28(8):1491–500.CrossRefGoogle Scholar
Woo, BK, Daly, JW, Allen, ECet al. Unrecognized medical disorders in older psychiatric inpatients in a senior behavioral health unit in a university hospital. J Geriatr Psychiatry Neurol 2003; 16(2): 121–5.CrossRefGoogle Scholar
Zayas, EM, Grossberg, GT. The treatment of psychosis in late life. J Clin Psychiatry 1998;59(1):5–10.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.